↓ Skip to main content

Dove Medical Press

Article Metrics

A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas

Overview of attention for article published in Drug Design, Development and Therapy, June 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter
1 tweeter
googleplus
1 Google+ user

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
21 Mendeley
Title
A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas
Published in
Drug Design, Development and Therapy, June 2015
DOI 10.2147/dddt.s79475
Pubmed ID
Authors

Yiquan Ke, Yonghong Zhang, Xinlin Sun, Min Huang, Jihui Wang, Xiao Liu

Abstract

In previous years, immunotoxins have been shown to be a greatly promising therapeutic tool for brain malignancies, such as gliomas. Human mesenchymal stem cells (hMSCs) exhibit tropism to tumor tissue. However, the effect of bispecific immunotoxins in malignant gliomas is still unknown. The aim of this study was to investigate the function of bispecific immunotoxins in human malignant gliomas. In the present study, the bispecific immunotoxin VEGF165-ephrin A1-PE38KDEL was established using deoxyribonucleic acid shuffling and cloning techniques. The VEGF165-ephrin A1-PE38KDEL was delivered by hMSCs to mouse malignant gliomas. The effects of the bispecific immunotoxins on glioma-derived blood vessels and vasculogenic mimicry to elucidate the molecular mechanisms underlying the antitumorigenic effects of immunotoxins were examined in vivo. In vitro, transfected hMSCs significantly inhibited the cell viability of gliomas cell lines U87 and U251 in a dose-dependent manner compared with untransfected hMSCs (P<0.01). In vivo, the intratumoral injection of engineered hMSCs was effective at inhibiting tumor growth in a malignant glioma tumor model. The bispecific immunotoxin secreted from hMSCs acts as a novel strategy for improving treatment options for malignant gliomas in the clinic.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 24%
Student > Master 3 14%
Professor > Associate Professor 2 10%
Student > Doctoral Student 1 5%
Other 1 5%
Other 5 24%
Unknown 4 19%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 4 19%
Medicine and Dentistry 4 19%
Pharmacology, Toxicology and Pharmaceutical Science 2 10%
Neuroscience 2 10%
Computer Science 1 5%
Other 2 10%
Unknown 6 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 June 2015.
All research outputs
#14,815,222
of 22,811,321 outputs
Outputs from Drug Design, Development and Therapy
#868
of 2,083 outputs
Outputs of similar age
#147,866
of 267,523 outputs
Outputs of similar age from Drug Design, Development and Therapy
#55
of 125 outputs
Altmetric has tracked 22,811,321 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,523 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 125 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.